Roche’s vision loss therapy faricimab extends time between treatments by up to four months
Results from four Phase III studies demonstrated non-inferior vision gains with extended dosing schedule
Read More
Tag: Diabetic macular edema
Roche’s faricimab hits the mark in diabetic macular edema study
Treatment demonstrated non-inferior visual acuity gains compared to Regeneron’s Eylea
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
